Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2− advanced breast cancer in China
While inavolisib plus palbociclib-fulvestrant significantly prolongs PFS and OS in PIK3CA-mutated HR+/HER2- ABC/MBC, it is not cost-effective at current prices in China. Strategic price adjustments or reimbursement negotiations are essential to improve economic feasibility and inform clinical and policy decisions.
Authors
- Cijuan Li
- Y U Zhang
- Yuanqing Huang (ORCID: https://orcid.org/0009-0009-5883-2946)
- Chang Wang (ORCID: https://orcid.org/0009-0005-1630-9453)
- Yingtao Lin
- Weiwei Huang
Institutions
- Fujian Medical University (CN)
- Fuzhou Maternity and Child Health Care Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fphar.2025.1742507
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province
- Wu Jieping Medical Foundation